Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Sep 05, 2023 9:10pm
53 Views
Post# 35621107

RE:RE:RE:Where Are WE ??

RE:RE:RE:Where Are WE ??You are right JC we just drift towards Sept. 22nd.  Total BS after close to 23 months we are still completely in the dark.   I like you am beginning to feel that this will not go well.  As I have said many times the management knows what is going on.
I have re-read the AGM announcement  (Aug. 8th) numerous times and one thing that jumps out at me is this:
"The meeting was also scheduled in response to a requisition for the company to call a meeting that shareholders received from Andrew Schutte on July 10, 2023, being a greater-than-5-per-cent shareholder of the company. Mr. Schutte requested that the company convene a meeting of shareholders to elect the slate of directors."

More specifically Andrew Schutte is requesting 6 Directors with the departure of Peter Lowry.  Also as usual it is all about:

"approval of a new equity incentive plan, which will enable the company to grant stock options, restricted share units, performance share units and deferred share units; and (iv) disinterested shareholder approval of the extension of the expiry date from July 30, 2023, to July 30, 2025, to 860,000 stock options granted to insiders of the company on July 30, 2018, which are each exercisable into one common share of the company at the exercise price of 43 cents per common share."

As that it ?  Nowhere in this N/R do they talk about announcing:

The Conclusion of the Shiseido Arbitration
Future of the Dermal Injector device
What is happening with Yofoto

Yes JC sadly I don't have a clue where this company or my investment is going.
<< Previous
Bullboard Posts
Next >>